Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clarification that OTC ephedrine proposal exempts ephedra requested in comments.

This article was originally published in The Tan Sheet

Executive Summary

FDA CLARIFICATION THAT OTC EPHEDRINE PROPOSAL DOES NOT EXTEND TO EPHEDRA REQUESTED in Sept. 27 comments submitted to the agency by a group involved in the marketing of ephedra herb tea. "Because an indiscriminate determination that all ephedrine is not GRAS would adversely affect the joint commenters' economic interests and their opportunity to continue marketing and consuming ephedra herb tea," the comments state, "they...feel compelled to request that the agency make clear that it does not intend for its final rule to affect ephedra herb food or dietary supplements."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel